CURE.X — Biocure Technology Cashflow Statement
0.000.00%
Last trade - 00:00- CA$0.77m
- CA$0.82m
- 17
- 35
- 28
- 15
Annual cashflow statement for Biocure Technology, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.08 | -1.87 | -0.403 | -1.49 | -0.262 |
| Depreciation | |||||
| Non-Cash Items | -0.09 | 0.537 | -0.916 | 1.02 | 0.008 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.8 | 0.249 | 0.494 | 0.253 | 0.268 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.31 | -1.08 | -0.826 | -0.217 | 0.014 |
| Capital Expenditures | -0.003 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.094 | 0.027 | 0.075 | 0.043 | 0 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.091 | 0.027 | 0.075 | 0.043 | 0 |
| Financing Cash Flow Items | — | 0.18 | 0.631 | 0.187 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.13 | 1.17 | 0.631 | 0.14 | 0 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.086 | 0.112 | -0.12 | -0.033 | 0.014 |